Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-tumor Double Checkpoint Inhibitors in Inoperable Lung Cancer
NCT06483347Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Apr 2024
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, pembrolizumab, durvalumab in lung cancer, sponsored by Second Affiliated Hospital of Guangzhou Medical University. Started Apr 2024; status: recruiting.
02
Drugs
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT06483347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06483347.